|
1
|
Heare T, Hensley MA and Dell’Orfano S:
Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr.
21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: a
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kakhki VR, Anvari K, Sadeghi R, Mahmoudian
AS and Torabian-Kakhki M: Pattern and distribution of bone
metastases in common malignant tumors. Nucl Med Rev Cent East Eur.
16:66–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu PK, Chen WM, Chen CF, Lee OK, Haung CK
and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis:
clinical results and prognostic factors in 91 patients. Jpn J Clin
Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sheu BC, Chang WC, Cheng CY, Lin HH, Chang
DY and Huang SC: Cytokine regulation networks in the cancer
microenvironment. Front Biosci. 13:6255–6268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson J and Balkwill F: The role of
cytokines in the epithelial cancer microenvironment. Semin Cancer
Biol. 12:113–120. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SH, Han SY, Azam T, Yoon DY and
Dinarello CA: Interleukin-32: a cytokine and inducer of TNFalpha.
Immunity. 22:131–142. 2005.PubMed/NCBI
|
|
8
|
Netea MG, Azam T, Ferwerda G, et al: IL-32
synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2
ligands for IL-1beta and IL-6 production through a caspase
1-dependent mechanism. Proc Natl Acad Sci USA. 102:16309–16314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi JD, Bae SY, Hong JW, et al:
Identification of the most active interleukin-32 isoform.
Immunology. 126:535–542. 2009. View Article : Google Scholar :
|
|
10
|
Yagi Y, Andoh A, Imaeda H, et al:
Interleukin-32α expression in human colonic subepithelial
myofibroblasts. Int J Mol Med. 27:263–268. 2011.
|
|
11
|
Yousif NG, Al-Amran FG, Hadi N, Lee J and
Adrienne J: Expression of IL-32 modulates NF-kappaB and p38 MAP
kinase pathways in human esophageal cancer. Cytokine. 61:223–227.
2013. View Article : Google Scholar
|
|
12
|
Lee HJ, Liang ZL, Huang SM, et al:
Overexpression of IL-32 is a novel prognostic factor in patients
with localized clear cell renal cell carcinoma. Oncol Lett.
3:490–496. 2012.PubMed/NCBI
|
|
13
|
Joosten LA, Heinhuis B, Netea MG and
Dinarello CA: Novel insights into the biology of interleukin-32.
Cell Mol Life Sci. 70:3883–3892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang YH, Park MY, Yoon DY, et al:
Dysregulation of over-expressed IL-32alpha in hepatocellular
carcinoma suppresses cell growth and induces apoptosis through
inactivation of NF-kappaB and Bcl-2. Cancer Lett. 318:226–233.
2012. View Article : Google Scholar
|
|
15
|
Oh JH, Cho MC, Kim JH, et al: IL-32gamma
inhibits cancer cell growth through inactivation of NF-kappaB and
STAT3 signals. Oncogene. 30:3345–3359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang CJ, Chien Y, Lu KH, et al:
Oct4-related cytokine effects regulate tumorigenic properties of
colorectal cancer cells. Biochem Biophys Res Commun. 415:245–251.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nold-Petry CA, Rudloff I, Baumer Y, et al:
IL-32 promotes angiogenesis. J Immunol. 192:589–602. 2014.
View Article : Google Scholar :
|
|
18
|
Ishigami S, Arigami T, Uchikado Y, et al:
IL-32 expression is an independent prognostic marker for gastric
cancer. Med Oncol. 30:4722013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sorrentino C and Di Carlo E: Expression of
IL-32 in human lung cancer is related to the histotype and
metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JS, Choi SY, Lee JH, et al:
Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7
cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr).
36:493–503. 2013. View Article : Google Scholar
|
|
21
|
Tsai CY, Wang CS, Tsai MM, et al:
Interleukin-32 increases human gastric cancer cell invasion
associated with tumor progression and metastasis. Clin Cancer Res.
20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng Q, Li S, Zhou Y, et al:
Interleukin-32 contributes to invasion and metastasis of primary
lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases
2 and 9 expression. Cytokine. 65:24–32. 2014. View Article : Google Scholar
|
|
23
|
Mabilleau G and Sabokbar A: Interleukin-32
promotes osteoclast differentiation but not osteoclast activation.
PLoS One. 4:e41732009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho KS, Park SH, Joo SH, Kim SH and Shin
CY: The effects of IL-32 on the inflammatory activation of cultured
rat primary astrocytes. Biochem Biophys Res Commun. 402:48–53.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Felaco P, Castellani ML, De Lutiis MA, et
al: IL-32: a newly-discovered proinflammatory cytokine. J Biol
Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI
|
|
26
|
Brader S and Eccles SA: Phosphoinositide
3-kinase signalling pathways in tumor progression, invasion and
angiogenesis. Tumori. 90:2–8. 2004.PubMed/NCBI
|
|
27
|
Balbin M, Pendas AM, Uria JA, Jimenez MG,
Freije JP and Lopez-Otin C: Expression and regulation of
collagenase-3 (MMP-13) in human malignant tumors. APMIS. 107:45–53.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ye Z, Jingzhong L, Yangbo L, Lei C and
Jiandong Y: Propofol inhibits proliferation and invasion of
osteosarcoma cells by regulation of microRNA-143 expression. Oncol
Res. 21:201–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Osaki M, Takeshita F, Sugimoto Y, et al:
MicroRNA-143 regulates human osteosarcoma metastasis by regulating
matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma O, Cai WW, Zender L, et al: MMP13,
Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9,
collaborate with p53 deficiency in mouse osteosarcoma progression.
Cancer Res. 69:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI
|
